Active Trials

These COVID-19 clinical trials are active and approved by Health Canada. Many more are pending approval and will be added in the days and weeks ahead.

Help us complete the circle. Add your trial to our list of active COVID-19 Canadian clinical trials and gain access to a wider participant registry.

Trial name A Randomized, Observer-Blind, Dose-escalation Phase I/II Clinical Trial of Ad5-nCoV Vaccine in Healthy Adults in Canada
Type of trial Phase I | Phase II
Trial ID NCT 04398147
Health Canada Status Health Canada approved
Trial Status Pending
Location
Nova Scotia
Trial description

This study is for healthy adults who do not have COVID-19. The study participants will receive Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5) (Ad5-nCoV). The study has two phases, Phase 1 is to see if the vaccine is safe to use in humans, and Phase 2 is to find an effective dose and timing for the vaccine.

Study team
Dr. Scott Halperin
Dr. Scott Halperin
MD
Canadian Center for Vaccinology
Joanne Langley
Dr. Joanne Langley
MD
Canadian Center for Vaccinology Dalhousie University, IWK Health Centre
Trial name A Randomized, Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)
Type of trial Phase III
Trial ID NCT 04348656
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario, Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Quebec, Saskatchewan, Northwest Territories, Nunavut, Yukon
Trial description

This study is for people who are hospitalized for COVID-19. All study participants will get convalescent plasma (a part of blood) to see if it prevents death and reduces intubation, and to see whether people are able to leave the intensive care unit and the hospital faster.

Study team
Donald Arnold
Dr. Donald Arnold
MD
McMaster University
Trial name CONCOR-KIDS: A randomized, multicentered, open-label Phase 2 clinical trial of the safety and efficacy of human Coronavirus-immune convalescent plasma for the treatment of COVID-19 disease in hospitalized children
Type of trial Phase II
Trial ID NCT04377568
Health Canada Status Health Canada approved
Trial Status Pending
Location
Alberta, British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, Saskatchewan
Trial description

This study is for children hospitalized with COVID-19. Study participants will know which therapy they receive, and it will be either (1) standard of care, or (2) convalescent plasma and standard of care. The study is to see if convalescent plasma improves clinical symptoms of COVID-19 and to see if it prevents death.

Study team
Dr. Julia Upton
Dr. Julia Upton
MD, MPH, Study Chair
Allergy and Immunology Department, The Hospital for Sick Children
Trial name Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients
Type of trial Phase II
Trial ID NCT 04321993
Health Canada Status Health Canada approved
Trial Status Open
Location
Nova Scotia
Trial description

This study is for people who are hospitalized for COVID-19. The study compares 4 different treatments to see if they will improve clinical symptoms, and to see if it will improve symptoms faster. The study participants will know which treatment they are getting, which will be one of: (1) Lopinavir/ritonavir, (2) Hydroxychloroquine sulfate, (3) Baricitinib, or (4) standard care.

Study team
Lisa Barrett
Dr. Lisa Barrett
MD
Dalhousie University